The RNA-focused biotechnology company had previously predicted those drugs, the transthyretin amyloidosis medications Amvuttra and Onpattro, would bring in $4.4 billion to $4.7 billion. But in an earnings report Thursday, it dropped that estimate to between $4.2 billion and $4.5 billion, revealing that Amvuttra’s early launch spike benefitted from “pent-up demand” that’s since “normalized.” Amvuttra sales totaled $1.01 billion for the quarter, or 3% below the average analyst estimate of $1.05 billion, according to Biliouris. Alnylam shares traded around $200 apiece by late Thursday afternoon, down from a $286 close the previous day. The earnings miss and guidance cut invites “major” questions on the outlook of Alnylam’s TTR business, wrote Jefferies analyst Faisal Khurshid.